AbbVie, Inc. (ABBV)
264.49
-0.47
(-0.18%)
USD |
NYSE |
Aug 24, 16:00
264.58
+0.09
(+0.03%)
After-Hours: 20:00
AbbVie EPS Diluted (Quarterly) : 2.033 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.033 |
| March 31, 2026 | 0.3861 |
| December 31, 2025 | 1.018 |
| September 30, 2025 | 0.0993 |
| June 30, 2025 | 0.524 |
| March 31, 2025 | 0.7201 |
| December 31, 2024 | -0.0181 |
| September 30, 2024 | 0.8753 |
| June 30, 2024 | 0.7679 |
| March 31, 2024 | 0.7665 |
| December 31, 2023 | 0.4577 |
| September 30, 2023 | 0.9977 |
| June 30, 2023 | 1.137 |
| March 31, 2023 | 0.1284 |
| December 31, 2022 | 1.391 |
| September 30, 2022 | 2.213 |
| June 30, 2022 | 0.5141 |
| March 31, 2022 | 2.513 |
| December 31, 2021 | 2.263 |
| September 30, 2021 | 1.777 |
| June 30, 2021 | 0.4217 |
| March 31, 2021 | 1.988 |
| December 31, 2020 | 0.0113 |
| September 30, 2020 | 1.291 |
| June 30, 2020 | -0.459 |
| Date | Value |
|---|---|
| March 31, 2020 | 2.019 |
| December 31, 2019 | 1.877 |
| September 30, 2019 | 1.264 |
| June 30, 2019 | 0.49 |
| March 31, 2019 | 1.65 |
| December 31, 2018 | -1.23 |
| September 30, 2018 | 1.81 |
| June 30, 2018 | 1.26 |
| March 31, 2018 | 1.74 |
| December 31, 2017 | 0.03 |
| September 30, 2017 | 1.01 |
| June 30, 2017 | 1.19 |
| March 31, 2017 | 1.06 |
| December 31, 2016 | 0.85 |
| September 30, 2016 | 0.97 |
| June 30, 2016 | 0.98 |
| March 31, 2016 | 0.83 |
| December 31, 2015 | 0.92 |
| September 30, 2015 | 0.74 |
| June 30, 2015 | 0.83 |
| March 31, 2015 | 0.63 |
| December 31, 2014 | -0.51 |
| September 30, 2014 | 0.31 |
| June 30, 2014 | 0.68 |
| March 31, 2014 | 0.61 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Biogen, Inc. | 0.6557 |
| Gilead Sciences, Inc. | -8.444 |
| Regeneron Pharmaceuticals, Inc. | 12.23 |
| Amgen, Inc. | 4.366 |
| REGENXBIO, Inc. | 0.4283 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 3.604B |
| Revenue (Quarterly) | 16.99B |
| Total Expenses (Quarterly) | 13.39B |
| Enterprise Value | 532.50B |
| Gross Profit Margin (Quarterly) | 74.71% |
| Profit Margin (Quarterly) | 21.21% |
| Earnings Yield | 1.34% |
| Operating Earnings Yield | 4.69% |
| Normalized Earnings Yield | 3.044 |